Akiyama Megumi, Inamoto Kyoko, Katayanagi Naoko, Toya Takashi, Najima Yuho, Kobayashi Takeshi, Sakamaki Hisashi, Ohashi Kazuteru, Doki Noriko
Hematology division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital.
Diabetology division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital.
Rinsho Ketsueki. 2022;63(8):876-879. doi: 10.11406/rinketsu.63.876.
We examined the incidence and clinical features of thyroid dysfunction in 661 patients who received allogeneic hematopoietic stem cell transplantation (allo-HSCT) in our hospital. At a median of 2.5 (1.0-11.3) years, 28 patients (4.2%) developed subclinical hypothyroidism, and 16 patients (2.4%) developed hypothyroidism. Eight of 16 patients (50%) with hypothyroidism were positive for anti-thyroid antibodies. Ten of 44 patients (22.7%) with thyroid dysfunction were discovered more than 5 years after allo-HSCT. Thyroid dysfunction with late onset was common in allo-HSCT recipients, and thyroid function should be monitored on a regular basis.
